A major change for restless legs treatment

In its 2025 guidelines for treating restless legs syndrome (RLS), the American Academy of Sleep Medicine stopped recommending the long-term use of dopamine agonist drugs, since they can eventually make RLS symptoms worse. Instead, the guidelines strongly recommend another class of medications as the first-line treatment: alpha-2-delta ligands, such as gabapentin (Neurontin), gabapentin enacarbil (Horizant), and pregabalin (Lyrica). Alpha-2-delta ligands do not make RLS symptoms worse.